Proposition - PharmXpert Academy

More documents

Recommendations

Info

The Korean Pharmaceutical Company List 345 No. Classification Section (Bio, Synthesis) The Name of Products Main Ingredient Use (Indications) Formulation The Date of Sales Expected Exporting Countries Etc. 13 Process improvement synthesis Gabalep Gabapentin Antiepileptics Cap 06.08 All the countries of the world 14 Process improvement synthesis Kmoxilin Amoxicillin. pot,clavulanate Antibiotics Inj,Tab,Dry syr 95.09 All the countries of the world 15 Process improvement synthesis Cefazolin Cefazolin sodium Antibiotics Inj 06.08 All the countries of the world 16 Process improvement synthesis Fosran Ceftezole sodium Antibiotics Inj 88.03 All the countries of the world 17 Process improvement synthesis Cefotazol Cefmetazole sodium Antibiotics Inj 86.10 All the countries of the world 18 Process improvement synthesis Penzal All the Acetaminophen,Is opropylantipyrine Digestives Tab 83.10 countries of the world 19 Process improvement synthesis Goowoonz yme Co-EnzymeQ10 Vitamins Tab 03.06 All the countries of the world 20 Process improvement synthesis Dongui cataplasm L-menthol, Acetic acid tocopherol, analgesic,antⅡnfla mmatory Patches 06.10 All the countries of the world 21 Process improvement synthesis Optilatan eye drop latanoprost Opthalmics Eye drop 05.07 All the countries of the world
346 2007 Korea Pharmaceutical Industry Directory 3. R&D Figures No Classification Section (Bio, Synthesis) 1 NCE synthesis 2 NCE 3 NCE semisynthesis 4 NCE synthesis 5 IMD synthesis 6 IMD synthesis The Name of Technology Camptothecin derivatives (potent activity and low toxicity) Fumagillin derivatives Higenamine derivatives potent PPAR-α agonist New salt (resinate) New salt (malate) Main Ingredient belotecan CKD-732 CKD-712 Use (Indications) anticancer (ovarian cancer, SCLC) semisynthesis antiangiogenenic agent anti-septic agent The Duration of Development The Stage of Development Future Plan - marketed licensing Expected Licencing (Domestic, Oversea) oversea (China, Taiwan) - phase I licensing oversea - phase I licensing oversea CKD-501 antidiabetes - phase Ⅱ licensing oversea clopidogrel resinate sibutramin e malate anticoagulant - registered licensing oversea (EU) antiobesity - marketed licensing oversea
Page 2 and 3:
2007 Korea Pharmaceutical Industry
Page 4 and 5:
2007 Korea Pharmaceutical Industry
Page 6 and 7:
27. ILYANG PHARM ·········
Page 8 and 9:
Chapter 1. Outline of The Project 2
Page 10 and 11:
Chapter 1. Outline of The Project 2
Page 12 and 13:
Chapter 2. Pharmaceutical Industry
Page 14 and 15:
Chapter 2. Pharmaceutical Industry
Page 16 and 17: Chapter 2. Pharmaceutical Industry
Page 36 and 37: The Annex
Page 38 and 39: 316 2007 Korea Pharmaceutical Indus
Page 40 and 41: The Korean Pharmaceutical Company L
Page 72 and 73: 4. Company Map The Korean Pharmace
Page 116 and 117:
The Korean Pharmaceutical Company L
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
4. Company Map The Korean Pharmace
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
show all

Proposition - PharmXpert Academy

Create successful ePaper yourself

Delete template?

Save as template?